Research
Print page Print page
Switch language
Hvidovre Hospital - a part of Copenhagen University Hospital
Published

Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes

Research output: Contribution to journalJournal articlepeer-review

View graph of relations

Sulfonylurea monotherapy is the standard treatment for patients with the most common form of permanent neonatal diabetes, KCNJ11 neonatal diabetes, but it is not always sufficient. For the first time, we present a case of successful use of a GLP-1 receptor agonist as add-on therapy in the treatment of a patient with KCNJ11 neonatal diabetes and insufficient effect of sulfonylurea monotherapy. Good glycaemic control was maintained with a HbA1c level of 48 mmol/mol (6.5%) at the end of 26 months' follow-up.

LEARNING POINTS: Genetic testing is important in patients with neonatal diabetes.Sulfonylurea is the standard treatment for patients with the most common mutation (KCNJ11).We present the novel use of a GLP-1 receptor agonist as effective add-on therapy in a patient with KCNJ11 neonatal diabetes and insufficient effect of sulfonylurea monotherapy.

Original languageEnglish
Article number002352
JournalEuropean journal of case reports in internal medicine
Volume8
Issue number3
Pages (from-to)1-4
Number of pages4
ISSN2284-2594
DOIs
Publication statusPublished - 31 Mar 2021

ID: 65018065